Navigation Links
Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine
Date:10/21/2011

H1N1 (A/California/07/2009) and H3N2 (A/Victoria/210/2009) strains. 

Safety was monitored for 21 days after vaccination. Blood specimens for immunogenicity (hemagglutination inhibition [HI assay]) were collected pre- and 21 days post-vaccination.

Immunogenicity and Safety Data In this investigational study, the immune responses to QIV were non-inferior to both of the control TIVs with respect to all four strains contained in the vaccine as measured by GMTs. For seroconversion rates, immune responses to QIV were non-inferior to those of the control TIVs with respect to all strains, except A/H1N1. 

Superiority was assessed by comparing antibody responses to each B strain in QIV with those induced by the TIV that did not contain the corresponding B strain.  For GMTs, superiority was demonstrated for the B/Florida (B2) strain in QIV, but not for B/Brisbane (B1). Although superiority of GMT for B/Brisbane was not achieved, the GMT was numerically superior and statistically non-inferior in QIV compared with the investigational TIV. 

For all groups in this investigational study, the most frequently reported solicited injection-site reaction was pain. The most frequently reported solicited systemic reactions were myalgia, headache and malaise. Three serious adverse events were reported in the study, but did not occur among QIV recipients and were not considered related to the study vaccine.

About Sanofi Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vacci
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
3. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
8. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
9. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
10. Sanofi-aventis Stands Behind the Safety of Lantus(R)
11. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 /PRNewswire/ ... new market research report is available in its ... Electronic Medical Records http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html ... fast-changing market for electronic medical records (EMR) for ... a comprehensive report of our findings. Our report ...
(Date:8/20/2014)... August 20, 2014 Glenmark ... Glenmark Pharmaceuticals Limited India (GPL), announces the discovery ... novel clinical development candidate, GBR 1302, a HER2xCD3 ... by the Glenmark Biologics Research Centre located in ... 1302 is based on Glenmark,s innovative BEAT antibody ...
(Date:8/19/2014)... Tenn. , Aug. 19, 2014   ... provide its patient experience technology to ... Under the five-year agreement, CarePoint Health will deploy ... Bayonne Medical Center, Christ Hospital and Hoboken University ... offers a range of software solutions to help ...
Breaking Medicine Technology:EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2
... 13 As biotechnology,pharmaceutical and medical device companies ... other parts of the world, such as Asia,Eastern ... firms, efforts to do business, according to an ... 2008 Clinical Trials Risk Map provides,those companies a ...
... MORRIS PLAINS, N.J., Aug. 13 Diakron Pharmaceuticals,Inc. ... agreement for a,novel investigational oral anticoagulant drug candidate ... Merck & Co. Inc. Under the,terms of the ... and,if approved, market and distribute the compound worldwide., ...
Cached Medicine Technology:Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc. 2
(Date:8/20/2014)... New York, NY (PRWEB) August 20, 2014 ... and architecture firm Perkins Eastman is pleased ... and design services in China and ... internationally recognized Principal Richard Sprow AIA has ... continue his 40-year career in healthcare planning and design ...
(Date:8/20/2014)... deadliest infectious diseases in the world, killing one to ... tuberculosis have long debated its origins. New research shows ... seals and sea lions that brought the disease to ... before Europeans landed on the continent. , The paper, ... New World Human Tuberculosis," was published in Nature ...
(Date:8/20/2014)... through fast-moving waters may be at risk, suggests new ... salmon encounter turbulent, fast-moving water such as rapids ... upstream using a behaviour known as "burst swimming" that ... sockeye passed through extremely fast-moving water, we started to ... spawning grounds," said Nicholas Burnett, a research biologist at ...
(Date:8/20/2014)... New York (PRWEB) August 20, 2014 ... the use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) ... notes that two U.S. Senators from New York are ... seek a recall of the devices. In a letter ... both Democrats, also implored the agency to seriously consider ...
(Date:8/20/2014)... 20, 2014) Research from Columbia University Medical Center ... stomach cancer growth and that blocking nerve signals using ... for the disease. The study was conducted by the ... Duan Chen, MD, PhD, in Norway and is published ... , "Scientists have long observed that human and mouse ...
Breaking Medicine News(10 mins):Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... President , , EAST ... SVNT ) today announced that its Board ... Committee")to oversee the regulatory and pre-launch activities for the ... comprised of independent Board members Lee S. Simon, M.D. ...
... CITY, Nov. 19 UCN, Inc.,(Nasdaq: UCNN ), ... one year renewable agreement for inContact(R) with a leading,healthcare provider ... , This new customer ... Response) solution with call routing between two of the company,s,contact ...
... Stayhealthy, Inc. and EF,Recovery announced today that they ... Fire Rescue Wellness Corporation to bring,revolutionary health and fitness ... "The health and safety of our ... Fire Chief of South Kitsap Fire Rescue. "As our ...
... This month the hit television,show ,Living in Style, ... in Style, is a half-hour news magazine television,series and ... clinically,proven ability to reduce body fat and increase lean ... premier brand of health supplements to,the consumer and utilizes ...
... People in the middle of,separation or divorce ... traditions are shattered; the hope and joy that ... depression. This year,s,economic downturn will add even more ... facing already-difficult financial circumstances. , ...
... LONDON, Nov. 19 With issues around patient comfort ... need to,consider patients, relief and welfare. This is leading ... are being used for a greater,number of patients and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , ...
Cached Medicine News:Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 2Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 3Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 4Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 5Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 6Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 7Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 8Health News:Leading Healthcare Provider Signs Agreement With UCN for inContact 2Health News:Washington Fire Firefighters Launch First of Its Kind Pilot Program on Health and Fitness 2Health News:Washington Fire Firefighters Launch First of Its Kind Pilot Program on Health and Fitness 3Health News:Clarinol(TM) CLA and Puregels(R) Featured on Hit Television Show 'Living in Style' 2Health News:Clarinol(TM) CLA and Puregels(R) Featured on Hit Television Show 'Living in Style' 3Health News:Holiday Season Amplifies Hurt of Separation and Divorce: Economic Woes Add to Pressure 2Health News:Patient Temperature Management Systems Enjoying Wider Usage 2Health News:Patient Temperature Management Systems Enjoying Wider Usage 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: